Triaziquone is a benzoquinone-containing alkylating agent. Triaziquone was shown to have activity in a variety of different animal tumors in vitro and in vivo and in human tumors. This agent presumably produces its antitumor effects by alkylation of cellular components, and has been shown to inhibit DNA and RNA synthesis. This agent is a substrate for both one and two-electron reducing agents and that the cytotoxic activity may result from protein alkylation and oxidative stress. Triaziquone was used clinically in the 1960s for the treatment of a number of cancers . It was used intravenously in the treatment of leukemias and lymphomas like chronic lymphocytic leukemia and Hodgkin's disease, and for ovarian cancer. The agent was also used as an ointment for basal cell skin cancers. Because of its toxicity to bone marrow and blood vessel walls it has been replaced by more effective agents and has not been used clinically for many years.